Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 3/20 | 0.71 |
| ▸ | TSHR | P16473 | 3/20 | 0.71 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.71 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.71 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.71 |
| ▸ | LMNA | P02545 | 2/20 | 0.71 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.71 |
| ▸ | THRB | P10828 | 1/20 | 0.71 |
| ▸ | ABCC8 | Q09428 | 1/20 | 0.71 |
| ▸ | KCNJ11 | Q14654 | 1/20 | 0.71 |
| ▸ | CA1 | P00915 | 3/20 | 0.54 |
| ▸ | CA12 | O43570 | 2/20 | 0.54 |
| ▸ | CA2 | P00918 | 2/20 | 0.54 |
| ▸ | CA9 | Q16790 | 2/20 | 0.54 |
| ▸ | MEN1 | O00255 | 2/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.36 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.36 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL718730 | 0.90 | CYP3A4 (0.67) | CYP3A4TSHRALDH1A1CYP2D6SMN1; SMN2 | |
| SCHEMBL5624381 | 0.87 | CYP3A4 (0.63) | CYP3A4TSHRALDH1A1CYP2D6SMN1; SMN2 | |
| SCHEMBL11803171 | 0.87 | CYP3A4 (0.63) | CYP3A4TSHRALDH1A1CYP2D6SMN1; SMN2 | |
| Diazoxide SCHEMBL41255 | 0.83 | ABCC8 (1.00) | CYP3A4TSHRALDH1A1CYP2D6SMN1; SMN2 | |
| Diazoxide SCHEMBL31112206 | 0.83 | ABCC8 (1.00) | CYP3A4TSHRALDH1A1CYP2D6SMN1; SMN2 | |
| SCHEMBL721585 | 0.81 | ABCC8 (0.79) | CYP3A4TSHRALDH1A1CYP2D6SMN1; SMN2 | |
| SCHEMBL8626914 | 0.78 | ALDH1A1 (0.60) | CYP3A4TSHRALDH1A1CYP2D6SMN1; SMN2 | |
| SCHEMBL7601849 | 0.75 | CA1 (0.64) | CYP3A4TSHRALDH1A1CYP2D6SMN1; SMN2 | |
| SCHEMBL7604772 | 0.75 | ALDH1A1 (0.71) | CYP3A4TSHRALDH1A1CYP2D6SMN1; SMN2 | |
| SCHEMBL717822 | 0.74 | CYP3A4 (0.42) | CYP3A4TSHRALDH1A1CYP2D6SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160361298-A1 | METHODS AND COMPOSITIONS FOR TREATING CANCER | GLOBAVIR BIOSCIENCES, INC. | 2016-12-15 | — | — | US | disclosed |
| US-20120053172-A1 | USE OF A COMBINATION OF DIAZOXIDE AND METFORMIN FOR TREATING OBESITY OR OBESITY RELATED DISORDERS | COOPERATIEVE MIRZORG U.A. | 2012-03-01 | — | — | US | disclosed |
| US-20100234362-A1 | USE OF DIAZOXIDE FOR SUPPRESSING THE PLASMA INSULIN LEVEL IN A MAMMAL | COOPERATIEVE MIRZORG U.A. (NL) | 2010-09-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120053172-A1 | USE OF A COMBINATION OF DIAZOXIDE AND METFORMIN FOR TREATING OBESITY OR OBESITY RELATED DISORDERS | GPR119, KCNJ1, GLP1R | CYP3A4 2309/4885TSHR 891/4885ALDH1A1 1266/4885 |
| US-20100234362-A1 | USE OF DIAZOXIDE FOR SUPPRESSING THE PLASMA INSULIN LEVEL IN A MAMMAL | KCNN4, KCNN1, GPR119 | CYP3A4 1361/4885TSHR 1048/4885ALDH1A1 1627/4885 |
| US-20160361298-A1 | METHODS AND COMPOSITIONS FOR TREATING CANCER | IDO2, IDO1, TDO2 | CYP3A4 3365/4885TSHR 3584/4885ALDH1A1 977/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.